{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:03:26Z","timestamp":1789229006420,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"am","delay-in-days":318,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.radonc.2023.109912","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T20:53:03Z","timestamp":1695243183000},"page":"109912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["A prospective registry study of stereotactic magnetic resonance guided radiotherapy (MRgRT) for primary liver tumors"],"prefix":"10.1016","volume":"189","author":[{"given":"Karl","family":"Bordeau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Michalet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Dorion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A\u00efcha","family":"Keskes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Valdenaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Debuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Cantaloube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Cabaill\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Draghici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ychou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Assenat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Jarlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gourgou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Guiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Ursic-Bedoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Aill\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Fenoglietto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Azria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Riou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.109912_b0005","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2023.109912_b0010","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2023.109912_b0015","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2012.05.007","article-title":"A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma","volume":"57","author":"Feng","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.radonc.2023.109912_b0020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jhep.2012.09.020","article-title":"Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors","volume":"58","author":"Kim","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.radonc.2023.109912_b0025","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/SLA.0b013e3181efc656","article-title":"A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria","volume":"252","author":"Huang","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.radonc.2023.109912_b0030","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.radonc.2018.12.005","article-title":"Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies","volume":"131","author":"Rim","year":"2019","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.radonc.2023.109912_b0035","doi-asserted-by":"crossref","unstructured":"Dawson LA, Winter K, Knox J, Zhu AX, Krishnan S, Guha C, et al. NRG\/RTOG 1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy (SBRT) Followed by Sorafenib in Hepatocellular Carcinoma (HCC) (NCT01730937). Int J Radiat Oncol Biol Phys 2022;114:1057. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.09.002.","DOI":"10.1016\/j.ijrobp.2022.09.002"},{"key":"10.1016\/j.radonc.2023.109912_b0040","doi-asserted-by":"crossref","unstructured":"Michalet M, Valdenaire S, Bordeau K, Azria D, Riou O. Chapter 15 - MR-guided radiotherapy for liver tumors: Hepatocarcinomas, cholangiocarcinomas, and liver metastases. In: Ozyar E, Onal C, Hackett SL, editors. Adv. Magn. Reson. Technol. Appl., vol. 8, Academic Press; 2022, p. 295\u2013314. https:\/\/doi.org\/10.1016\/B978-0-323-91689-9.00015-7.","DOI":"10.1016\/B978-0-323-91689-9.00015-7"},{"key":"10.1016\/j.radonc.2023.109912_b0045","first-page":"851","article-title":"Stereotactic body radiotherapy of primary liver tumours: Indications and new techniques","volume":"26","author":"Bordeau","year":"2022","journal-title":"Cancer Radiother J Soc Francaise Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109912_b0050","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s00432-020-03480-8","article-title":"MRI-guided stereotactic radiation therapy for hepatocellular carcinoma: a feasible and safe innovative treatment approach","volume":"147","author":"Boldrini","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109912_b0055","first-page":"e5774","article-title":"Real-time magnetic resonance-guided liver stereotactic body radiation therapy: An institutional report using a magnetic resonance-linac system","volume":"11","author":"Feldman","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.radonc.2023.109912_b0060","doi-asserted-by":"crossref","unstructured":"Hall WA, Straza MW, Chen X, Mickevicius N, Erickson B, Schultz C, et al. Initial clinical experience of Stereotactic Body Radiation Therapy (SBRT) for liver metastases, primary liver malignancy, and pancreatic cancer with 4D-MRI based online adaptation and real-time MRI monitoring using a 1.5 Tesla MR-Linac. PloS One 2020;15:e0236570. https:\/\/doi.org\/10.1371\/journal.pone.0236570.","DOI":"10.1371\/journal.pone.0236570"},{"key":"10.1016\/j.radonc.2023.109912_b0065","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.radonc.2017.11.032","article-title":"Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen","volume":"126","author":"Henke","year":"2018","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.radonc.2023.109912_b0070","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.adro.2018.08.005","article-title":"A multi-institutional experience of MR-guided liver stereotactic body radiation therapy","volume":"4","author":"Rosenberg","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.109912_b0075","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.radonc.2021.06.005","article-title":"Ablative radiotherapy for liver tumors using stereotactic MRI-guidance: A prospective phase I trial","volume":"170","author":"van Dams","year":"2022","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.radonc.2023.109912_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.610637","article-title":"Magnetic resonance-guided stereotactic body radiotherapy of liver tumors: Initial clinical experience and patient-reported outcomes","volume":"11","author":"Weykamp","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2023.109912_b0085","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.1002\/cam4.4139","article-title":"Clinical outcomes of stereotactic magnetic resonance image-guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis","volume":"10","author":"Yoon","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.radonc.2023.109912_b0090","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/cancers15010007","article-title":"Stereotactic MR-guided adaptive radiotherapy for pancreatic tumors: Updated results of the montpellier prospective registry study","volume":"15","author":"Bordeau","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.radonc.2023.109912_b0095","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/jcm12010291","article-title":"Stereotactic MR-guided radiotherapy for adrenal gland metastases: First clinical results","volume":"12","author":"Michalet","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.radonc.2023.109912_b0100","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.842402","article-title":"Stereotactic MR-guided radiotherapy for pancreatic tumors: dosimetric benefit of adaptation and first clinical results in a prospective registry study","volume":"12","author":"Michalet","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2023.109912_b0105","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3390\/jcm12031183","article-title":"Stereotactic MR-guided radiotherapy for liver metastases: First results of the montpellier prospective registry study","volume":"12","author":"Bordeau","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.radonc.2023.109912_b0110","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.radonc.2023.109912_b0115","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.prro.2021.09.004","article-title":"External beam radiation therapy for primary liver cancers: An ASTRO clinical practice guideline","volume":"12","author":"Apisarnthanarax","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.109912_b0120","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","article-title":"Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines","volume":"32","author":"Vogel","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2023.109912_b0125","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.3390\/cancers13194853","article-title":"Image-guided liver stereotactic body radiotherapy using VMAT and real-time adaptive tumor gating: Evaluation of the efficacy and toxicity for hepatocellular carcinoma","volume":"13","author":"Cantaloube","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.radonc.2023.109912_b0130","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00432-015-1929-y","article-title":"The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT)","volume":"141","author":"Scorsetti","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109912_b0135","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijrobp.2019.12.004","article-title":"Curative irradiation treatment of hepatocellular carcinoma: A multicenter phase 2 trial","volume":"107","author":"Durand-Labrunie","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109912_b0140","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/j.ijrobp.2011.04.011","article-title":"Stereotactic body radiotherapy for primary hepatocellular carcinoma","volume":"81","author":"Andolino","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.radonc.2023.109912_b0145","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/aae7fd","article-title":"The radiobiological impact of motion tracking of liver, pancreas and kidney SBRT tumors in a MR-linac","volume":"63","author":"Al-Ward","year":"2018","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.radonc.2023.109912_b0150","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.clon.2019.01.012","article-title":"Stereotactic body radiotherapy for small unresectable hepatocellular carcinomas","volume":"31","author":"Yeung","year":"2019","journal-title":"Clin Oncol R Coll Radiol G B"},{"key":"10.1016\/j.radonc.2023.109912_b0155","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ijrobp.2017.02.095","article-title":"Long-term survival analysis of stereotactic ablative radiotherapy versus liver resection for small hepatocellular carcinoma","volume":"98","author":"Su","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109912_b0160","article-title":"Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma","author":"Wahl","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109912_b0165","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.2017.75.3228","article-title":"Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: Analysis of the national cancer database","volume":"36","author":"Rajyaguru","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109912_b0170","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.radonc.2019.12.004","article-title":"Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: Meta-analyses and a systematic review","volume":"145","author":"Lee","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109912_b0175","doi-asserted-by":"crossref","first-page":"e90327","DOI":"10.1371\/journal.pone.0090327","article-title":"Stereotactic body radiotherapy-induced arterial hypervascularity of non-tumorous hepatic parenchyma in patients with hepatocellular carcinoma: Potential pitfalls in tumor response evaluation on multiphase computed tomography","volume":"9","author":"Park","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.radonc.2023.109912_b0180","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.ijrobp.2017.08.022","article-title":"Imaging findings within the first 12 months of hepatocellular carcinoma treated with stereotactic body radiation therapy","volume":"102","author":"Mendiratta-Lala","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109912_b0185","doi-asserted-by":"crossref","first-page":"W812","DOI":"10.2214\/AJR.12.10169","article-title":"Tumor response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis","volume":"201","author":"Sanuki","year":"2013","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.radonc.2023.109912_b0190","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1186\/s12885-016-2512-x","article-title":"Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma","volume":"16","author":"Que","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2023.109912_b0195","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.radonc.2015.04.006","article-title":"Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma","volume":"115","author":"Huertas","year":"2015","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.radonc.2023.109912_b0200","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1186\/s12885-017-3847-7","article-title":"Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy","volume":"17","author":"Cozzi","year":"2017","journal-title":"BMC Cancer"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023898061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023898061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:27:46Z","timestamp":1759123666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814023898061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":40,"alternative-id":["S0167814023898061"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109912","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A prospective registry study of stereotactic magnetic resonance guided radiotherapy (MRgRT) for primary liver tumors","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109912","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109912"}}